Overdose, Drug Clinical Trial
— ROAROfficial title:
Reducing Overdose After Release From Incarceration
NCT number | NCT03902821 |
Other study ID # | ROAR |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 17, 2019 |
Est. completion date | November 30, 2023 |
Verified date | April 2024 |
Source | Oregon Health and Science University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective of the ROAR project is to evaluate an Oregon Department of Corrections (ODOC) pilot program that combines the use of extended-release naltrexone (XR-NTX) and Certified Recovery Mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and non-fatal opioid overdoses among female adults released from prison.
Status | Completed |
Enrollment | 65 |
Est. completion date | November 30, 2023 |
Est. primary completion date | July 14, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Be a woman (including transgender and non-binary adults assigned to women's housing at CCCF) - 18 years of age or older with a known release date during the 18-month recruitment period - Be released to Marion, Multnomah, Clackamas or Washington County, Oregon - Be willing and able to provide informed consent and HIPAA authorization for medical record abstraction and linkage to state administrative data - Meet DSM-V (Diagnostic and Statistical Manual) criteria for moderate or severe opioid use disorder - Be willing to establish ongoing care at the community SUD (substance use disorder) treatment site in county of release - Be willing to initiate XR-NTX prior to release from incarceration - Not be currently pregnant and must be willing to take at least one evidence-based measure to avoid becoming pregnant during treatment with XR-NTX Exclusion Criteria: A participant will be excluded if she - Has a severe medical, psychiatric, or substance use disorder that, in the opinion of the CCCF Qualified Mental Health Professional (QMHP)or study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study due to imminent risk of death - Has another medical condition leading XR-NTX to be contraindicated - Has chronic pain requiring ongoing pain management with opioid analgesics - Received methadone or buprenorphine maintenance therapy in the 4 weeks prior to consent - Has a planned surgery or other procedure within the next 4 weeks that will require opioid analgesia |
Country | Name | City | State |
---|---|---|---|
United States | Oregon Department of Corrections | Wilsonville | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon Health and Science University | Bridgeway Recovery, CODA Inc., Health Insight, Oregon Department of Corrections, Oregon State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Any Opioid Overdose | This is a binary outcome indicating a fatal or non-fatal opioid-related overdose event | 6 months after release from incarceration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04134767 -
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
|
N/A | |
Recruiting |
NCT05329142 -
ASSIST: A Surveillance Study of Illicit Substance Toxicity
|